Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
0.999
-0.021 (-2.05%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ovid Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 15.02 | 27.04 | 44.87 | 187.8 | 72.03 | 41.9 | Upgrade
|
| Short-Term Investments | 47.7 | 78.79 | 84.13 | - | - | 34.84 | Upgrade
|
| Cash & Short-Term Investments | 62.71 | 105.83 | 129 | 187.8 | 72.03 | 76.74 | Upgrade
|
| Cash Growth | -27.98% | -17.96% | -31.31% | 160.71% | -6.13% | 84.91% | Upgrade
|
| Other Receivables | - | - | - | - | 0.14 | 1.13 | Upgrade
|
| Receivables | - | - | - | - | 0.14 | 1.13 | Upgrade
|
| Prepaid Expenses | 3.12 | 3.76 | 2.38 | 2.68 | 2.67 | 1.94 | Upgrade
|
| Total Current Assets | 65.83 | 109.6 | 131.38 | 190.48 | 74.84 | 79.81 | Upgrade
|
| Property, Plant & Equipment | 13.59 | 14.66 | 16.07 | 0.24 | 0.14 | 0.07 | Upgrade
|
| Long-Term Investments | 21.13 | 17.63 | 5.62 | 1.63 | - | - | Upgrade
|
| Other Intangible Assets | 0.16 | 0.18 | 0.22 | 0.26 | 0.32 | 0.47 | Upgrade
|
| Other Long-Term Assets | 1.96 | 1.96 | 1.97 | 1.93 | 0.63 | 0.49 | Upgrade
|
| Total Assets | 102.65 | 144.03 | 155.27 | 194.54 | 75.93 | 80.84 | Upgrade
|
| Accounts Payable | 2.71 | 3.7 | 1.95 | 7.13 | 5.45 | 3.26 | Upgrade
|
| Accrued Expenses | 7.61 | 6.53 | 4.5 | 7.67 | 12.03 | 7.27 | Upgrade
|
| Current Portion of Leases | 1.31 | 1.25 | 0.53 | - | - | - | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 2.21 | - | Upgrade
|
| Other Current Liabilities | - | - | - | - | 2.37 | 0.01 | Upgrade
|
| Total Current Liabilities | 11.63 | 11.47 | 6.99 | 14.8 | 22.06 | 10.53 | Upgrade
|
| Long-Term Leases | 13.76 | 14.76 | 16 | - | - | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 10.17 | - | Upgrade
|
| Other Long-Term Liabilities | 0.97 | 30 | - | - | 0.06 | 0.29 | Upgrade
|
| Total Liabilities | 26.36 | 56.23 | 22.99 | 14.8 | 32.29 | 10.82 | Upgrade
|
| Common Stock | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.05 | Upgrade
|
| Additional Paid-In Capital | 371.23 | 365.59 | 357.77 | 351.03 | 337.76 | 283.12 | Upgrade
|
| Retained Earnings | -295.05 | -277.87 | -225.53 | -171.36 | -294.19 | -213.16 | Upgrade
|
| Comprehensive Income & Other | 0.04 | 0 | -0.04 | - | - | 0 | Upgrade
|
| Total Common Equity | 76.29 | 87.8 | 132.27 | 179.75 | 43.63 | 70.02 | Upgrade
|
| Shareholders' Equity | 76.29 | 87.8 | 132.27 | 179.75 | 43.63 | 70.02 | Upgrade
|
| Total Liabilities & Equity | 102.65 | 144.03 | 155.27 | 194.54 | 75.93 | 80.84 | Upgrade
|
| Total Debt | 15.08 | 16 | 16.54 | - | - | - | Upgrade
|
| Net Cash (Debt) | 47.64 | 89.83 | 112.47 | 187.8 | 72.03 | 76.74 | Upgrade
|
| Net Cash Growth | -32.69% | -20.13% | -40.11% | 160.71% | -6.13% | 84.91% | Upgrade
|
| Net Cash Per Share | 0.67 | 1.27 | 1.60 | 2.76 | 1.23 | 1.96 | Upgrade
|
| Filing Date Shares Outstanding | 71.01 | 70.71 | 70.49 | 70.37 | 65.75 | 54.71 | Upgrade
|
| Total Common Shares Outstanding | 71.01 | 70.69 | 70.47 | 70.36 | 65.74 | 54.71 | Upgrade
|
| Working Capital | 54.2 | 98.12 | 124.39 | 175.68 | 52.78 | 69.28 | Upgrade
|
| Book Value Per Share | 1.07 | 1.24 | 1.88 | 2.55 | 0.66 | 1.28 | Upgrade
|
| Tangible Book Value | 76.14 | 87.61 | 132.05 | 179.49 | 43.31 | 69.56 | Upgrade
|
| Tangible Book Value Per Share | 1.07 | 1.24 | 1.87 | 2.55 | 0.66 | 1.27 | Upgrade
|
| Machinery | 1.51 | 1.46 | 1.42 | 0.5 | 0.32 | 0.19 | Upgrade
|
| Leasehold Improvements | 0.31 | 0.31 | 0.31 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.